Objective
=========

We present a post hoc analysis from 3 phase III clinical trials examining the effects of mometasone furoate/ formoterol (MF/F) combination therapy on asthma deterioration (ie, severe asthma exacerbation) in subjects previously uncontrolled on low-, medium-, or high-dose inhaled corticosteroids (ICS).

Methods
=======

A 2--3-week run-in period with twice daily (BID) MF-100µg, MF-200µg, or MF-400µg was performed before subject (≥12y) randomization to BID: MF/F-100/10µg, MF-100µg, F-10µg, or placebo for 26weeks (n=746); MF/F-200/10mg, MF-200µg, F-10µg, or placebo for 26weeks (n=781); MF/F-200/10µg, MF/F-400/10µg, or MF-400µg for 12weeks (n=728 ). Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1s \[FEV~1~\]; 30% decrease in peak expiratory flow \[PEF\] on ≥2 consecutive days; or clinically judged deterioration \[ie, emergency treatment, hospitalization, or treatment with excluded medications\]) was a co-primary endpoint for studies, and a secondary endpoint for study. Post hoc pair-wise comparisons of pooled MF/F vs MF, F, and placebo treatment groups were performed.

Results
=======

Sample sizes in this pooled analysis were: MF/F, n=861; MF, n=620; F, n=390; placebo, n=384. There was a significantly lower incidence of asthma deterioration with MF/F= 17.2% vs MF=26.1% (*P*=.002), F=49.5% (*P*\<.001), and placebo550.8% (*P*\<.001). Incidence rates for asthma deterioration subtypes were: FEV~1~ reduction: MF/F=7.0%, MF=10.0%, F=13.8%, placebo=17.7%; PEF reduction: MF/F=7.5%, MF=12.6%, F=27.2%, placebo=26.3%; clinically judged deterioration: MF/F=2.1%, MF=2.6%, F=6.7%, placebo=5.2%.

Conclusion
==========

MF/F-treated subjects experienced a significantly lower rate of asthma deterioration compared with MF, F, and placebo in subjects previously uncontrolled on low-, medium-, or high-dose ICS in this pooled analysis.
